ArticleJournal of biochemical and molecular toxicology2026
Molecular Docking and Experimental Evaluation of Trolox and Neocuproine in Targeting Neuroinflammation in Neuropathic Pain Model.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was carried out to evaluate the therapeutic efficacy of Neocuproine/Trolox treatment on chronic neuropathy induced by Chronic Constriction Injury (CCI). Rats (n = 40) were grouped as Sham, CCI, CCI+Trolox, and CCI+Neocuproine. Rats with proven neuropathy were given 80 mg/kg/day (i.p.) Trolox and 100 μM/day (i.p.) Neocuproine for 7 days. Open field and tail withdrawal tests were conducted at baseline and on days 7 and 14. ELISA test was employed in analyzing IL 1β, IL 10, TNF-α, and TGF-β levels in spinal cord and cortex tissues of rats. To explore potential mechanistic interactions, molecular docking was conducted with the key cytokine receptor. On day 14, a significant decrease in total path taken, number of frames entered, and delay values were observed in CCI group compared to the control, whereas significant increases were observed in total path taken, number of frames entered, and delay values in the CCI+Neocuproine/Trolox treatment groups compared to CCI group (p < 0.05 for all). Docking analyses were performed for Neocuproine/Trolox. In comparison to the sham group, IL‑1β and TNF-α levels in spinal cord and cortex tissues were higher, while IL‑10 and TGF-β levels were lower (p < 0.05). Neocuproine/Trolox treatments reduced proinflammatory cytokine levels and elevated anti-inflammatory cytokine levels in CCI rats on day 14 (p < 0.05 for all). Considering the docking score of Neocuproine/Trolox, high scores were observed, especially with TNF-α and TGF-β receptor. The results suggest that Neocuproine/Trolox treatments induce thermal anti-hyperalgesic behaviors in CCI-induced pain, showing significant improvements in locomotor activity, and achieve these by reducing the production of proinflammatory cytokines and elevating that of anti-inflammatory cytokines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.